Amlitelimab is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis.

TG Therapeutics TGTX announced that it has completed enrollment in the phase III study evaluating the subcutaneous ...

Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

It will soon be time to process spring-born calves, which brings up the topic of best management practices and following Beef ...

In this segment, Dr. Morrison discusses the clinical evidence supporting subcutaneous immunotherapy and explains the concept ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

De FIA heeft een technical directive rondgestuurd die een trucje van Mercedes en Red Bull moet indammen. Kimi Antonelli vindt het niet zo erg.

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...